Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof

Abstract

Compounds and compositions for stabilizing microtubules are disclosed. Also disclosed are methods of inhibiting, preventing, regulating, modulating, attenuating, stabilizing, or affecting microtubule formation or function. Methods of treating, preventing or inhibiting diseases and disorders associated with microtubule formation, function, or both by administering a microtubule stabilizing agent such as coumarin is also disclosed.

1 - 28 . (canceled)  
     
     
         29 . A kit for modulating or stabilizing microtubules comprising at least one coumarin compound packaged together with at least one supplementary compound selected from group of antineoplastic agents, antiproliferative agents, anti-inflammatory agents, antifungal agents, and combinations thereof.  
     
     
         30 . The kit of  claim 29 , wherein the coumarin compound is coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7-dihydroxycoumarin (esculetin), 3,6,7-trihydroxycoumarin, warfarin, or warfarin sodium.  
     
     
         31 . The kit of  claim 29 , wherein the supplementary compound is taxol, estramustine, taxotere, vinblastine, vincristine, discodermolide, griseofulvin, or amphotericin B.  
     
     
         32 . The kit of  claim 29 , wherein the coumarin compound and the supplementary compound are packaged together as a single pharmaceutical composition.  
     
     
         33 . The kit of  claim 29 , and further comprising instructions for use.  
     
     
         34 . The kit of  claim 29 , and further comprising a drug delivery device.  
     
     
         35 . A kit comprising at least one coumarin compound packaged together with at least one supplementary compound selected from group of antineoplastic agents, antiproliferative agents, anti-inflammatory agents, antifungal agents, and combinations thereof.  
     
     
         36 . The kit of  claim 35 , wherein the coumarin compound is coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7-dihydroxycoumarin (esculetin), 3,6,7-trihydroxycoumarin, warfarin, or warfarin sodium.  
     
     
         37 . The kit of  claim 35 , wherein the supplementary compound is taxol, estramustine, taxotere, vinblastine, vincristine, discodermolide, griseofulvin, or amphotericin B.  
     
     
         38 . The kit of  claim 35 , wherein the coumarin compound and the supplementary compound are packaged together as a single pharmaceutical composition.  
     
     
         39 . The kit of  claim 35 , and further comprising instructions for use.  
     
     
         40 . The kit of  claim 35 , and further comprising a drug delivery device.